Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Protagonist Therapeutics (NASDAQ:PTGX) Pulls Back 6.0% This Week, but Still Delivers Shareholders Fantastic 75% CAGR Over 3 Years
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $65
Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics | 10-Q: Q1 2025 Earnings Report
